Skip to main content

Table 2 Summary of clinical findings

From: CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer

Parameter No. of patients %
Response* (n = 71)   
  Pathologic complete response 7 9.9
  Clinical complete response 4 5.6
  Partial response 22 31.0
  Stable disease 33 46.5
  Progressive disease 5 7.0
Symptom relief (n = 53)   
  Complete relief 30 56.6
  Partial relief 17 32.1
  No relief 6 11.3
  1. *: 14 patients underwent radical resections (R0) post-chemoradiation.